33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot/phase II study evaluating pembrolizumab plus standard-ofcare chemotherapy in metastatic triple-negative breast cancer, with companion comprehensive immunological monitoring
    Meeting Abstract

    Page, D.; Yu, W.; Conlin, A.; Ruzich, J.; Lewis, S.; Acheson, A.; Kemmer, K.; Perlewitz, K.; Moxon, N. M.; Mellinger, S.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • KEYNOTE-013: An open-label, multicohort phase Ib trial of pembrolizumab in patients with advanced hematologic malignancies
    Meeting Abstract

    Kline, J.; Armand, P.; Kuruvilla, J.; Moskowitz, C.; Hamadani, M.; Ribrag, V.; Zinzani, P. L.; Chlosta, S.; Thompson, S.; Balakumaran, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Meeting Abstract

    Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A.; Sonpavde, G.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: The phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Rini, B. I.; Choueiri, T. K.; Mariani, M.; Albiges, L.; Haanen, J. B.; Atkins, M. B.; Larkin, J.; Schmidinger, M.; Magazzù, D.; di Pietro, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • A turbocharged chimeric antigen receptor against prostate cancer
    Meeting Abstract

    Zhao, Z.; Hamieh, M.; Eyquem, J.; Gunset, G.; Bander, N.; Sadelain, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Converting tumor-mediated PD-L1 inhibition into CAR T cell costimulation to potentiate adoptive T cell therapy
    Meeting Abstract

    Adusumilli, P. S.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Pre-existing immunity to oncolytic virus potentiates its therapeutic efficacy
    Meeting Abstract

    Ricca, J.; Merghoub, T.; Wolchok, J. D.; Zamarin, D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Intestinal microbiota and relapse after hematopoietic-cell transplantation
    Meeting Abstract

    Peled, J.; Devlin, S.; Staffas, A.; Lumish, M.; Rodriguez, K. P.; Ahr, K.; Perales, M.; Giralt, S.; Taur, Y.; Pamer, E.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients
    Meeting Abstract

    Zappasodi, R.; Li, Y.; Qi, J.; Wong, P.; Sirard, C.; Postow, M.; Newman, W.; Koon, H.; Velcheti, V.; Callahan, M. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save